RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024May 02, 2024 - Oncology was the top therapy area for M&A deals in Q1 2024, with a total deal value of $29bn.
Globaldata reports that given that the biopharmaceutical industry can overcome challenges imposed by the FTC, the remainder of 2024 is poised for continued M&A investment from large biopharmaceutical companies, which could accelerate research and development and the launch of innovative drugs.
https://www.pharmaceutical-technology.com/analyst-comment/ma-revival-deals-q1-2024/?cf-view